A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Xiujuan Wu, Peng Tang, Shifei Li, Shushu Wang, Yueyang Liang, Ling Zhong, Lin Ren, Ting Zhang and Yi Zhang ()
Additional contact information
Xiujuan Wu: Third Military Medical University
Peng Tang: Third Military Medical University
Shifei Li: Third Military Medical University
Shushu Wang: Third Military Medical University
Yueyang Liang: Third Military Medical University
Ling Zhong: Third Military Medical University
Lin Ren: Third Military Medical University
Ting Zhang: Third Military Medical University
Yi Zhang: Third Military Medical University

Nature Communications, 2018, vol. 9, issue 1, 1-8

Abstract: Abstract Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3–4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-03210-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03210-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-03210-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().